Publications by authors named "G E Searles"
Background: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.
View Article and Find Full Text PDFArticle Synopsis
- The treat-to-target (T2T) strategy is increasingly used in medicine for optimal treatment decisions and may be effective for managing IL-17 inhibitors in autoimmune diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- The article aims to evaluate the effectiveness and safety of IL-17 inhibitors using the T2T approach based on clinical trial evidence.
- Results indicate that IL-17 inhibitors like secukinumab and ixekizumab significantly outperform placebo and improve outcomes for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with low rates of serious side effects.
Health literacy refers to the comprehension required to make well-informed decisions regarding one's health. It is a critical component in helping patients to understand how to take their medications appropriately. However, many patients do not possess the comprehension necessary for medication adherence.
View Article and Find Full Text PDFBackground: Non-melanoma skin cancer (NMSC), including basal and squamous cell carcinoma, represents the most common malignancy.
Objective: The aim of this document is to provide guidance to Canadian health care practitioners on NMSC management.
Methods: After conducting a literature review, the group developed recommendations for prevention, management, and treatment of basal cell carcinomas, squamous cell carcinomas, and actinic keratoses.
Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis.
Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis.